← Therapeutics
Details checkedStrong evidenceCheckedcompany
ACOU085 by Acousia Therapeutics
Also known as: ACOU085, Bimokalner, ACOU085 (bimokalner)
Acousia Therapeutics GmbH
Company
Acousia Therapeutics GmbH
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 2
Status
Active
Target Gene
KCNQ4
Route / Mode
Intratympanic injection
Confidence
93%
Status Confidence
Status confirmed
Evidence Strength
Strong evidence
Last Reviewed
2026-05-31
Geography
Germany
Population
adult, age-related, cisplatin-ototoxicity
Trial IDs
1
Mechanism
Kv7.4 potassium-channel modulator designed to acutely enhance outer hair-cell function and protect cochlear outer hair cells from injury.
Indications
Notes
Verified active clinical-stage Acousia program. Earlier public development focused on presbycusis Phase 1b; latest public update emphasizes Phase 2 PROHEAR in cisplatin-induced ototoxicity prevention.
Evidence & Sources
5 structured sourcescompany
Supports: canonicalName, aliases, company, modality, mechanism, targetGene, indications, stage...
IDs: ACOU085, Bimokalner, PROHEAR
company
Supports: indications, stage, populationTags, keyEvents
IDs: ACOU085
company
Supports: stage, status, populationTags, keyEvents
IDs: ACOU085
company
Supports: company, allCompanies, indications, notes
IDs: ACOU085, ACOU082
clinicaltrials
Supports: trialIds, stage, status, route, populationTags, geography
IDs: NCT06521190
Key Events
Clinical Trials (1)
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2